Published in Nat Med on January 28, 2010
Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol (2010) 3.53
Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature (2010) 2.90
Chikungunya virus arthritis in adult wild-type mice. J Virol (2010) 2.16
Emerging biomedical applications of synthetic biology. Nat Rev Genet (2011) 2.05
Arthritogenic alphaviruses--an overview. Nat Rev Rheumatol (2012) 1.87
Impact of Wolbachia on infection with chikungunya and yellow fever viruses in the mosquito vector Aedes aegypti. PLoS Negl Trop Dis (2012) 1.72
Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines (2012) 1.69
Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog (2011) 1.62
Chikungunya virus: evolution and genetic determinants of emergence. Curr Opin Virol (2011) 1.57
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med (2012) 1.29
High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl Trop Dis (2015) 1.28
Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol (2012) 1.21
A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine (2011) 1.20
T-cell epitope vaccine design by immunoinformatics. Open Biol (2013) 1.20
Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol (2013) 1.19
Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine (2011) 1.17
Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol J (2011) 1.16
Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis (2014) 1.15
Chikungunya infection in India: results of a prospective hospital based multi-centric study. PLoS One (2012) 1.11
Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife (2013) 1.10
Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum (2012) 1.10
Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS (2010) 1.05
Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine (2012) 1.03
Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis (2014) 1.01
Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine (2013) 0.99
Protective and Pathogenic Responses to Chikungunya Virus Infection. Curr Trop Med Rep (2015) 0.99
BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology (2013) 0.98
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97
Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. PLoS One (2014) 0.97
Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol (2014) 0.97
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Animal Models of Chikungunya Virus Infection and Disease. J Infect Dis (2016) 0.96
Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand. Virol J (2014) 0.96
Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis (2013) 0.95
A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol (2012) 0.95
Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate. PLoS Negl Trop Dis (2015) 0.95
A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis (2013) 0.94
Prime-boost immunization strategies against Chikungunya virus. J Virol (2014) 0.92
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J (2010) 0.92
Antiviral perspectives for chikungunya virus. Biomed Res Int (2014) 0.92
A nonhuman primate model of chikungunya disease. J Clin Invest (2010) 0.91
Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest (2017) 0.89
A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J Virol (2012) 0.88
A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice. PLoS Negl Trop Dis (2015) 0.87
Functional characterization of the alphavirus TF protein. J Virol (2013) 0.86
Chlorogenic acid inhibits the replication and viability of enterovirus 71 in vitro. PLoS One (2013) 0.85
Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation. J Virol (2012) 0.85
A Review of Chikungunya Virus-induced Arthralgia: Clinical Manifestations, Therapeutics, and Pathogenesis. Open Rheumatol J (2016) 0.85
DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice. J Infect Dis (2014) 0.85
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis (2016) 0.83
Subviral particle as vaccine and vaccine platform. Curr Opin Virol (2014) 0.83
The Global Virus Network: Challenging chikungunya. Antiviral Res (2015) 0.83
H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One (2011) 0.83
Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. J Clin Microbiol (2013) 0.82
Low temperature-dependent salmonid alphavirus glycoprotein processing and recombinant virus-like particle formation. PLoS One (2011) 0.82
The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains. J Virol (2013) 0.82
Current strategic thinking for the development of a trivalent alphavirus vaccine for human use. Am J Trop Med Hyg (2014) 0.82
A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice. PLoS Negl Trop Dis (2014) 0.82
Novel vaccine strategies against emerging viruses. Curr Opin Virol (2013) 0.81
Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proc Natl Acad Sci U S A (2015) 0.81
Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice. J Virol (2013) 0.81
Reemergence of Chikungunya virus in Indian Subcontinent. Indian J Virol (2010) 0.81
Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice. Virol J (2011) 0.81
Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Cell Rep (2015) 0.80
Do we need a vaccine against chikungunya? Pathog Glob Health (2015) 0.80
Approaches to the treatment of disease induced by chikungunya virus. Indian J Med Res (2013) 0.80
Inactivation of Chikungunya virus by 1,5 iodonapthyl azide. Virol J (2012) 0.80
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int (2013) 0.80
Intercellular Extensions Are Induced by the Alphavirus Structural Proteins and Mediate Virus Transmission. PLoS Pathog (2016) 0.80
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line. PLoS One (2014) 0.79
Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. J Virol (2015) 0.78
Probing the early temporal and spatial interaction of the Sindbis virus capsid and E2 proteins with reverse genetics. J Virol (2012) 0.78
Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. PLoS Negl Trop Dis (2014) 0.78
Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model). Pathogens (2015) 0.78
Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine. J Chromatogr A (2014) 0.78
Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype. J Virol (2014) 0.78
Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions. J Pharm Sci (2013) 0.78
Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. BMC Microbiol (2014) 0.78
DNA-launched live-attenuated vaccines for biodefense applications. Expert Rev Vaccines (2016) 0.78
CD8+ T cells control Ross River virus infection in musculoskeletal tissues of infected mice. J Immunol (2014) 0.77
Kinetic characterization of trans-proteolytic activity of Chikungunya virus capsid protease and development of a FRET-based HTS assay. Sci Rep (2015) 0.77
Evaluation of protective efficacy induced by virus-like particles containing a Trichinella spiralis excretory-secretory (ES) protein in mice. Parasit Vectors (2016) 0.77
Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals. Clin Vaccine Immunol (2014) 0.77
A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. MAbs (2015) 0.77
Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine. Viral Immunol (2013) 0.77
Development of Vaccines for Chikungunya Fever. J Infect Dis (2016) 0.76
Chikungunya vaccines in development. Hum Vaccin Immunother (2016) 0.76
Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells. Hum Gene Ther (2011) 0.76
Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera. PLoS Negl Trop Dis (2016) 0.76
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother (2015) 0.75
Palmitoylation of Sindbis virus TF protein regulates its plasma membrane localization and subsequent incorporation into virions. J Virol (2016) 0.75
Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate. PLoS Negl Trop Dis (2016) 0.75
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus. J Infect Dis (2016) 0.75
Next generation sequencing of DNA-launched Chikungunya vaccine virus. Virology (2016) 0.75
Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus. Bioengineered (2014) 0.75
Intact glycopeptide characterization using mass spectrometry. Expert Rev Proteomics (2016) 0.75
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. Am J Trop Med Hyg (2016) 0.75
EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol (1999) 27.52
The alphaviruses: gene expression, replication, and evolution. Microbiol Rev (1994) 16.68
EMAN2: an extensible image processing suite for electron microscopy. J Struct Biol (2006) 14.70
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog (2007) 10.38
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol (2007) 6.16
Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis (2009) 4.72
The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) (1956) 4.63
The pH independence of mammalian retrovirus infection. J Gen Virol (1990) 3.68
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog (2008) 3.40
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Characterization of reemerging chikungunya virus. PLoS Pathog (2007) 3.22
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold. Cell (2001) 2.96
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol (2007) 2.86
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
Entomology. A mosquito goes global. Science (2008) 2.68
Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis (2009) 2.54
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg (2000) 2.39
Virus-like particles as immunogens. Trends Microbiol (2003) 2.38
Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines (2007) 1.79
Chimeric alphavirus vaccine candidates for chikungunya. Vaccine (2008) 1.78
Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine (1986) 1.74
Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am (2008) 1.69
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Virus-like particles-universal molecular toolboxes. Curr Opin Biotechnol (2007) 1.48
Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol (1971) 1.35
Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine (2009) 1.32
Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg (1967) 1.19
Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol (1970) 1.12
Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis (1998) 1.09
Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine. J Virol (2005) 0.85
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog (2007) 10.38
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
A structural perspective of the flavivirus life cycle. Nat Rev Microbiol (2005) 5.02
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Outcome of the first electron microscopy validation task force meeting. Structure (2012) 4.35
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol (2003) 4.11
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 3.90
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
Conformational changes of the flavivirus E glycoprotein. Structure (2004) 3.66
Structures of immature flavivirus particles. EMBO J (2003) 3.62
West Nile virus: where are we now? Lancet Infect Dis (2004) 3.49
Structure of West Nile virus. Science (2003) 3.48
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? Virol J (2008) 3.39
Structure of the cell-puncturing device of bacteriophage T4. Nature (2002) 3.32
Three-dimensional rearrangement of proteins in the tail of bacteriophage T4 on infection of its host. Cell (2004) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol (2010) 3.18
Sequencing of Culex quinquefasciatus establishes a platform for mosquito comparative genomics. Science (2010) 3.18
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
The structure of the phage T4 DNA packaging motor suggests a mechanism dependent on electrostatic forces. Cell (2008) 3.07
The structure and evolution of the major capsid protein of a large, lipid-containing DNA virus. Proc Natl Acad Sci U S A (2002) 3.07
Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med (2010) 3.06
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science (2007) 2.95
Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol (2002) 2.89
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
The tail structure of bacteriophage T4 and its mechanism of contraction. Nat Struct Mol Biol (2005) 2.82
Placement of the structural proteins in Sindbis virus. J Virol (2002) 2.81
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
Conservation of the capsid structure in tailed dsDNA bacteriophages: the pseudoatomic structure of phi29. Mol Cell (2005) 2.80
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol (2003) 2.67
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol (2004) 2.63
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States. Virology (2003) 2.59
Structural and functional similarities between the capsid proteins of bacteriophages T4 and HK97 point to a common ancestry. Proc Natl Acad Sci U S A (2005) 2.53
Giant Marseillevirus highlights the role of amoebae as a melting pot in emergence of chimeric microorganisms. Proc Natl Acad Sci U S A (2009) 2.52
Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains. J Virol (2005) 2.52
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40